Financials
- Market Capitalization 11.36 B
- Employee 3 000
- Founded 1976
- CEO Charles R. Kummeth
- Website www.bio-techne.com
- Headquarter Minnesota, United States
- FIGI BBG000C15114
- Industry Biotechnology
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 824 | HALO Halozyme Therapeutics, Inc. - Common Stock | 106.92 USD | -0.13% | +0.68% | +28.70% | +60.06% | 12.14 B USD | ||
| 852 | SMMT Summit Therapeutics Inc. - Common Stock | 14.33 USD | +0.70% | +12.83% | +13.64% | -27.84% | 11.43 B USD | ||
| 875 | CYTK Cytokinetics, Incorporated - Common Stock | 77.90 USD | -1.64% | +0.78% | -2.34% | +34.08% | 10.83 B USD | ||
| 880 | AXSM Axsome Therapeutics, Inc. - Common Stock | 206.27 USD | -0.42% | -0.46% | -12.56% | +58.43% | 10.80 B USD |
Frequently asked questions about Bio-Techne Corp.
What is the Bio-Techne Corp. stock price today?
The current price of Bio-Techne Corp. (TECH) is 72.47. Over the past 24 hours, the stock has changed by +0.12%. Follow the TECH chart for real-time price dynamics.
What is the stock ticker of Bio-Techne Corp.?
Bio-Techne Corp. trades under the ticker TECH. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Bio-Techne Corp. stock going up?
TECH has changed by +0.19% over the last week, +0.47% over the last month, and +33.83% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of Bio-Techne Corp.?
Bio-Techne Corp. currently has a market capitalization of 11.36 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
Does Bio-Techne Corp. release financial reports?
Yes. You can track Bio-Techne Corp. financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.
What were Bio-Techne Corp. earnings last quarter?
Last quarter, Bio-Techne Corp. reported earnings of 0.35 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was Bio-Techne Corp. revenue for the last quarter?
Bio-Techne Corp. reported quarterly revenue of 321.19 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was Bio-Techne Corp. net income for the last quarter?
Bio-Techne Corp. reported net income of 54.62 M for the last quarter. The previous quarter showed 51.05 M, which means net income changed by +7.00%.
Does Bio-Techne Corp. pay dividends?
Bio-Techne Corp. paid a dividend per share of 0.32. The current dividend yield is 0.45%. Dividend data can help income-focused investors evaluate the stock.
Is Bio-Techne Corp. a good dividend stock?
Bio-Techne Corp. currently has a dividend yield of 0.45%. Previously, the dividend yield was 1.07%, compared with 0.95% a year earlier. When evaluating dividend stocks, investors should also consider earnings, cash flow, and the sustainability of future dividend payments.
How many employees does Bio-Techne Corp. have?
As of the latest available data, Bio-Techne Corp. has 3 000 employees. Workforce size can provide additional context about the company's scale and operations.
What is Bio-Techne Corp. EBITDA?
Bio-Techne Corp. EBITDA is 98.42 M, and its EBITDA margin is 30.64%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Bio-Techne Corp. stock?
You can buy Bio-Techne Corp. (TECH) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Bio-Techne Corp. stock?
Investing in Bio-Techne Corp. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the TECH chart and related analysis on metatrader.com as part of your research.